BioNTech’s (BNTX) “Buy” Rating Reiterated at Canaccord Genuity Group

Canaccord Genuity Group reaffirmed their buy rating on shares of BioNTech (NASDAQ:BNTX) in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a $171.00 target price on the stock.

Several other equities analysts have also recently weighed in on BNTX. Bank of America lifted their price objective on BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, September 19th. HSBC increased their price objective on shares of BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research report on Monday, October 7th. The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and upped their target price for the company from $90.00 to $137.00 in a research report on Friday, November 8th. Finally, Jefferies Financial Group upgraded BioNTech from a “hold” rating to a “buy” rating and lifted their price target for the stock from $96.00 to $150.00 in a research report on Tuesday, September 17th. Four equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $137.54.

BioNTech Trading Down 3.7 %

Shares of BioNTech stock opened at $99.72 on Thursday. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The company has a market capitalization of $23.91 billion, a P/E ratio of -47.49 and a beta of 0.26. The company has a fifty day moving average of $113.54 and a 200 day moving average of $97.24.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of ($1.26) by $2.07. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.73 EPS. On average, sell-side analysts anticipate that BioNTech will post -3.47 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

A number of large investors have recently made changes to their positions in BNTX. Vestcor Inc bought a new stake in BioNTech during the 3rd quarter valued at about $784,000. Y Intercept Hong Kong Ltd bought a new stake in shares of BioNTech during the third quarter valued at approximately $718,000. XTX Topco Ltd bought a new stake in shares of BioNTech during the third quarter valued at approximately $459,000. State Street Corp boosted its holdings in shares of BioNTech by 2.0% in the third quarter. State Street Corp now owns 155,867 shares of the company’s stock valued at $18,512,000 after purchasing an additional 3,014 shares during the period. Finally, Redmile Group LLC bought a new position in BioNTech in the third quarter worth approximately $18,345,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.